HEALTHCARE COSTS OF INFLAMMATORY BOWEL DISEASE IN THE BIOLOGIC ERA- A STUDY OF 2,451 PATIENTS WITH TWELVE YEARS FOLLOW-UP EVALUATION

Author(s)

Odes S1, Vardi H2, Greenberg D2, Schwartz D3, Friger M2, Chernin E2, Sarid O2, Slonim-Nevo V2
1Ben-Gurion University of the Negev, Beer Sheva, Israel, 2Ben-Gurion University of the Negev, Beer-Sheva, Israel, 3Soroka Medical Center, Beer-Sheva, Israel

Presentation Documents

OBJECTIVES: Up-to-date knowledge of healthcare costs (HCC) in patients with inflammatory bowel disease (IBD) in the biologic era is still incomplete. In particular, long-term observational studies of HCC are lacking.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PGI38

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Gastrointestinal Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×